[Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia].
Ekaterina Yu ChelyshevaA N PetrovaOleg A ShukhovA V BykovaI S NemchenkoM A GurianovaN N TsybaAnna G TurkinaPublished in: Terapevticheskii arkhiv (2022)
The rate of WS was 27% that is in a good concordance with the data of the other TFR studies. A longer period of TKI exposure, older age and the history of locomotion system diseases were associated with the development of the WS. We found for the first time that WS was not observed in patients with pregnancy. There was no association of WS development and the rate of molecular relapses.